ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,049 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 226-250 of 1,000 matching filings.

Per page
25
Current page
10
F-6 File 333-284374

F-6 filing

Filing date
21 Jan 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER

Filing date
21 Jan 2025
Reporting date
21 Jan 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL

Filing date
17 Jan 2025
Reporting date
17 Jan 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Jan 2025
Reporting date
02 Jan 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU

Filing date
26 Dec 2024
Reporting date
26 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL

Filing date
23 Dec 2024
Reporting date
23 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTORATE CHANGE

Filing date
16 Dec 2024
Reporting date
16 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC

Filing date
05 Dec 2024
Reporting date
05 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL

Filing date
04 Dec 2024
Reporting date
04 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
02 Dec 2024
Reporting date
02 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Dec 2024
Reporting date
02 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER

Filing date
25 Nov 2024
Reporting date
25 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
20 Nov 2024
Reporting date
20 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA

Filing date
18 Nov 2024
Reporting date
18 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Nov 2024
Reporting date
15 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Nov 2024
Reporting date
15 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Nov 2024
Reporting date
13 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA INVESTS $3.5 BILLION IN US

Filing date
12 Nov 2024
Reporting date
12 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

KOMET PHASE III TRIAL MET PRIMARY ENDPOINT

Filing date
12 Nov 2024
Reporting date
12 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

9M AND Q3 2024 RESULTS

Filing date
12 Nov 2024
Reporting date
12 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN

Filing date
12 Nov 2024
Reporting date
12 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS

Filing date
08 Nov 2024
Reporting date
08 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Nov 2024
Reporting date
01 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN CHINA PRESIDENT UNDER INVESTIGATION

Filing date
30 Oct 2024
Reporting date
30 Oct 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
28 Oct 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .